Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

PURPOSE: The response rate of head and neck squamous cell carcinoma (HNSCC) patients to cetuximab therapy is only 15–20%, despite frequent EGFR overexpression. Since immunosuppression is common in HNSCC, we hypothesized that adding a pro-inflammatory TLR8 agonist to cetuximab therapy might result in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Shayan, Gulidanna, Kansy, Benjamin A., Gibson, Sandra P., Srivastava, Raghvendra M., Bryan, James Kyle, Bauman, Julie E., Ohr, James, Kim, Seungwon, Duvvuri, Umamaheswar, Clump, David A., Heron, Dwight E., Johnson, Jonas T., Hershberg, Robert M., Ferris, Robert L.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754237/
https://ncbi.nlm.nih.gov/pubmed/29061643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0357
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars